Ultragenyx Pharmaceutical price to sales ratio RARE

Market value divided by revenue over the last twelve months, since 2018.

Today, Oct 23, 2026: 2.2×
8-year median: 10.5×
Against its 8-year history: 2nd; percentile: 0 is its lowest day, 100 its highest
8-year range: 2.0× to 167×
Peer median: 2.0×

Ultragenyx Pharmaceutical's price to sales ratio is 2.2× as of Oct 23, 2026.

That is below its 8-year median of 10.5×, lower than on 98% of days in the last 8 years.

Over that time it ranged from 2.0× in Sep 2026 to 167× in Sep 2018.

The median for 10 large drugmakers of a similar size is 2.0×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	2.2×	2.0×	5.0×
2025	5.2×	4.2×	8.0×
2024	7.7×	7.3×	11.3×
2023	9.6×	5.8×	9.6×
2022	9.5×	7.2×	16.9×
2021	15.9×	14.4×	46.0×
2020	39.3×	20.9×	49.1×
2019	29.7×	24.7×	76.1×
2018	56.3×	52.2×	167×

Against its peers

Companies in Drug Manufacturers - General nearest Ultragenyx Pharmaceutical's size, closest first, today.

Company	Price to sales ratio
RAREUltragenyx Pharmaceutical	2.2×
PAHCPhibro Animal Health	1.0×
ANABAnaptysbio	n/m
PCRXPacira BioSciences	1.9×
ANIPANI Pharmaceuticals	1.7×
OMEROmeros	n/m
HRMYHarmony Biosciences	2.2×
AMPHAmphastar Pharmaceuticals	1.5×
PBHPrestige Consumer Healthcare	2.0×
NRIXNurix Therapeutics	3.9×
ABUSArbutus Biopharma	4.6×
Peer median	2.0×

Where Ultragenyx Pharmaceutical ranks

#45of 157Large drugmakers with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Ultragenyx Pharmaceutical

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.